share_log

Los Angeles Capital Management LLC Has $1.34 Million Holdings in Meridian Bioscience, Inc. (NASDAQ:VIVO)

Los Angeles Capital Management LLC Has $1.34 Million Holdings in Meridian Bioscience, Inc. (NASDAQ:VIVO)

洛杉磯資本管理公司持有134萬美元的子午線生物科學公司股份(納斯達克代碼：VIVO)
Defense World ·  2022/08/11 06:21

Los Angeles Capital Management LLC lessened its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) by 11.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 51,531 shares of the company's stock after selling 6,740 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.12% of Meridian Bioscience worth $1,338,000 at the end of the most recent quarter.

洛杉磯資本管理有限責任公司最近提交給美國證券交易委員會的文件顯示，該公司今年第一季度將其在納斯達克(Sequoia Bioscience，Inc.)股票的持倉比例降低了11.6%。該公司在本季度出售了6,740股後，持有51,531股該公司股票。截至最近一個季度末，洛杉磯資本管理公司擁有Meridian Bioscience公司約0.12%的股份，價值1,338,000美元。

A number of other institutional investors and hedge funds have also added to or reduced their stakes in VIVO. Advisor Group Holdings Inc. grew its position in shares of Meridian Bioscience by 6.1% during the 1st quarter. Advisor Group Holdings Inc. now owns 16,453 shares of the company's stock worth $464,000 after buying an additional 940 shares during the period. Teton Advisors Inc. grew its position in shares of Meridian Bioscience by 6.4% during the 4th quarter. Teton Advisors Inc. now owns 25,000 shares of the company's stock worth $510,000 after buying an additional 1,500 shares during the period. Horan Securities Inc. acquired a new stake in shares of Meridian Bioscience during the 4th quarter worth approximately $33,000. Prospera Financial Services Inc acquired a new stake in shares of Meridian Bioscience during the 1st quarter worth approximately $42,000. Finally, Rhumbline Advisers grew its position in shares of Meridian Bioscience by 1.4% during the 4th quarter. Rhumbline Advisers now owns 126,390 shares of the company's stock worth $2,578,000 after buying an additional 1,778 shares during the period. Institutional investors and hedge funds own 94.72% of the company's stock.

其他一些機構投資者和對衝基金也增持或減持了vivo的股份。Advisor Group Holdings Inc.在第一季度將其在Meridian Bioscience的股票頭寸增加了6.1%。Advisor Group Holdings Inc.在此期間又購買了940股，現在擁有16,453股該公司股票，價值46.4萬美元。Teton Advisors Inc.在第四季度將其在Meridian Bioscience的股票頭寸增加了6.4%。Teton Advisors Inc.在此期間又購買了1,500股，現在持有25,000股該公司股票，價值51萬美元。霍蘭證券公司在第四季度收購了Meridian Bioscience的新股份，價值約3.3萬美元。普羅斯佩拉金融服務公司在第一季度收購了Meridian Bioscience的新股份，價值約42,000美元。最後，Rhumbline Advisers在第四季度將其在子午線生物科學公司的股票頭寸增加了1.4%。在此期間，Rhumbline Advisers又購買了1,778股，現在擁有126,390股該公司股票，價值2,578,000美元。機構投資者和對衝基金持有該公司94.72%的股票。

Get
到達
Meridian Bioscience
子午線生物科學
alerts:
警報：

Meridian Bioscience Stock Performance

子午線生物科學股票表現

NASDAQ VIVO opened at $32.75 on Thursday. The company has a fifty day simple moving average of $30.77 and a 200 day simple moving average of $27.32. Meridian Bioscience, Inc. has a 12-month low of $17.20 and a 12-month high of $34.38. The company has a current ratio of 3.85, a quick ratio of 2.60 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.43 billion, a P/E ratio of 33.08 and a beta of 0.28.

納斯達克VIVO週四開盤報32.75美元。該公司的50日簡單移動均線切入位為30.77美元，200日簡單移動均線切入位為27.32美元。Meridian Bioscience，Inc.的股價為17.20美元，為12個月低點，12個月高位為34.38美元。該公司的流動比率為3.85，速動比率為2.60，債務權益比率為0.07。該公司市值14.3億美元，市盈率為33.08倍，貝塔係數為0.28。

Insider Activity at Meridian Bioscience

子午線生物科學的內部活動

In related news, CEO John P. Kenny sold 13,559 shares of Meridian Bioscience stock in a transaction on Friday, June 24th. The shares were sold at an average price of $30.00, for a total value of $406,770.00. Following the completion of the sale, the chief executive officer now owns 265,131 shares of the company's stock, valued at approximately $7,953,930. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Meridian Bioscience news, CEO John P. Kenny sold 13,559 shares of the firm's stock in a transaction on Friday, June 24th. The stock was sold at an average price of $30.00, for a total transaction of $406,770.00. Following the transaction, the chief executive officer now directly owns 265,131 shares in the company, valued at approximately $7,953,930. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John P. Kenny sold 44,651 shares of the firm's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $29.72, for a total value of $1,327,027.72. Following the transaction, the chief executive officer now owns 265,131 shares in the company, valued at $7,879,693.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,647 shares of company stock valued at $3,600,868. 2.30% of the stock is owned by company insiders.
在相關新聞中，首席執行官約翰·P·肯尼在6月24日(星期五)的一次交易中出售了13,559股Meridian Bioscience股票。這些股票的平均價格為30.00美元，總價值為406,770.00美元。出售完成後，首席執行官現在擁有265,131股公司股票，價值約7,953,930美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，可以通過美國證券交易委員會網站訪問該文件。在Meridian Bioscience的其他消息中，首席執行官約翰·P·肯尼在6月24日星期五的一次交易中出售了13,559股該公司的股票。該股以30.00美元的平均價格出售，總成交金額為406,770.00美元。交易完成後，這位首席執行官現在直接擁有該公司265,131股，價值約7,953,930美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過這個超級鏈接獲得。此外，首席執行官約翰·P·肯尼在6月22日星期三的一次交易中出售了44,651股公司股票。這些股票的平均價格為29.72美元，總價值為1,327,027.72美元。交易完成後，這位首席執行官現在擁有該公司265,131股，價值7879,693.32美元。此次拍賣的披露信息可在此處找到。在過去的90天裏，內部人士賣出了119,647股公司股票，價值3,600,868美元。2.30%的股份由公司內部人士持有。

Analyst Upgrades and Downgrades

分析師升級和下調評級

VIVO has been the subject of several recent analyst reports. StockNews.com downgraded shares of Meridian Bioscience from a "buy" rating to a "hold" rating in a research report on Tuesday. William Blair downgraded shares of Meridian Bioscience from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 7th. Finally, HC Wainwright downgraded shares of Meridian Bioscience from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $30.00 to $34.00 in a research report on Friday, July 8th.

Vivo是最近幾份分析師報告的主題。在週二發佈的一份研究報告中，StockNews.com將Merdian Bioscience的股票評級從買入下調至持有。在7月7日週四的一份研究報告中，威廉·布萊爾將子午線生物科學公司的股票評級從“跑贏大盤”下調至“市場表現”。最後，在7月8日星期五的一份研究報告中，HC Wainwright將Meridian Bioscience的股票評級從買入下調至中性，並將該股的目標價從30.00美元上調至34.00美元。

Meridian Bioscience Profile

子午線生物科學概況

(Get Rating)

(獲取評級)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Meridian Bioscience，Inc.是一家生命科學公司，主要開發、製造、分銷和銷售診斷試劑盒，主要用於胃腸道和呼吸道傳染病以及全球範圍內的血鉛水平升高。該公司通過診斷和生命科學部門開展業務。診斷部門提供測試平臺，包括Revogene品牌下的實時PCR擴增；Alethia品牌下的等温DNA擴增；Curian品牌下使用熒光化學的側向流動免疫分析；免疫卡和免疫卡STAT下的快速免疫分析！品牌；Premier品牌的酶聯免疫檢測；LeadCare品牌的陽極溶出伏安法；以及H.

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
  • Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
  • The 2 Dow Stocks with Decade-Long Win Streaks on the Line
  • Could Rite Aid Be an Acquisition Target, Again?
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • 免費獲取StockNews.com關於子午線生物科學的研究報告(Vivo)
  • 大型和小型石油和天然氣類股盈利後反彈
  • 連續十年上漲的兩隻道指股票
  • Rite Aid會再次成為收購目標嗎？
  • 投資石油股票的方式和原因
  • 投資黃金股票的方式和原因

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating).

想看看其他對衝基金持有哪些VIVO嗎？請訪問HoldingsChannel.com以獲取Merdian Bioscience，Inc.(納斯達克：VIVO-GET Rating)的最新13F備案和內幕交易信息。

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

接受《子午線生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收對Meridian Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論